Radiopharmaceutical for Nuclear Medicine Companies, Innovation and Product Evolutio

Top Vendors in the Radiopharmaceutical for Nuclear Medicine Market & Their Offering

Novartis AG

Headquarters: Basel, Switzerland
Offerings: Targeted radioligand therapies, including Lutathera® and Pluvicto®, focused on oncology and theranostic applications.

GE HealthCare Technologies Inc.

Headquarters: Illinois, USA
Offerings: PET and SPECT imaging systems, radiopharmaceuticals, cyclotrons, and digital solutions supporting nuclear medicine diagnostics and precision imaging.

Cardinal Health, Inc.

Headquarters: Ohio, USA
Offerings: Production and distribution of diagnostic radiopharmaceuticals, PET tracers, nuclear pharmacy services, and supply chain solutions for hospitals and diagnostic centers.

Lantheus Holdings, Inc.

Headquarters: Massachusetts, USA
Offerings: Diagnostic radiopharmaceuticals for PET and SPECT imaging, including agents for cardiology and oncology, along with AI-enabled imaging solutions.

Curium Pharma

Headquarters: Paris, France
Offerings: Diagnostic and therapeutic radiopharmaceuticals, including SPECT and PET tracers, oncology-focused agents, and global radioisotope manufacturing and distribution services.

Value Chain Analysis

R&D 

• Radiopharmaceutical R&D centers on developing precise radioactive compounds for disease imaging (PET/SPECT) and targeted radionuclide therapies, mainly in oncology. The focus is shifting toward personalized, theranostic, and highly selective agents that improve diagnostic accuracy and treatment outcomes.
• Key players: Novartis, Bayer, GE HealthCare, Siemens Healthineers, Lantheus, Curium, Telix Pharmaceuticals.

Regulatory Approvals

• Regulatory approval of radiopharmaceuticals in nuclear medicine follows a dual framework, requiring adherence to drug safety, quality, and clinical effectiveness standards alongside strict radiation protection and handling regulations. This ensures both patient safety and therapeutic reliability.
• Key players: Novartis, Bayer, Curium, Eckert & Ziegler, Cardinal Health, NorthStar Medical Radioisotopes, Telix Pharmaceuticals.

Patient Support and Services

• Patient support and services in nuclear medicine radiopharmaceuticals are designed to enhance patient safety, improve imaging precision, and maximize treatment effectiveness while carefully controlling radiation exposure throughout diagnosis and therapy.
• Key players: GE HealthCare, Siemens Healthineers, Bracco, Curium, Lantheus, Bayer, and AAA (Advanced Accelerator Applications).

Market Growth

The global radiopharmaceutical for nuclear medicine market size was estimated at USD 7.75 billion in 2025 and is predicted to increase from USD 8.43 billion in 2026 to approximately USD 17.91 billion by 2035, expanding at a CAGR of 8.74% from 2026 to 2035.

What are the Recent Developments in the Radiopharmaceutical for Nuclear Medicine Market?

• In April 2024, Curium’s acquisition of Eczacıbaşı-Monrol Nuclear Product Co. strengthens its global presence by expanding PET and SPECT capabilities. The deal enhances infrastructure and supports the advancement of innovative radionuclides and radiopharmaceutical pipelines for both diagnostic and therapeutic applications.
• In February 2024, Lantheus Holdings, Inc. partnered with the National Institute on Aging–supported CLARiTI consortium to support Alzheimer’s disease research. Under this collaboration, the consortium is using Lantheus’ clinical-stage F-18 PET imaging agent, MK-6240, to advance imaging-based investigations into Alzheimer’s pathology.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com